- Home
- HFFG vs BDTX Comparison
HFFG vs BDTX Comparison
Compare HFFG & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HFFG | BDTX |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | 54 |
| Industry | Food Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.8M | 126.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HFFG | BDTX |
|---|---|---|
| Price | $1.48 | $2.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.40 |
| AVG Volume (30 Days) | 154.0K | ★ 818.6K |
| Earning Date | 03-12-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | ★ $1,225,541,000.00 | $70,000,000.00 |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $3.35 | N/A |
| P/E Ratio | ★ N/A | $5.87 |
| Revenue Growth | ★ 4.10 | N/A |
| 52 Week Low | $1.47 | $1.20 |
| 52 Week High | $4.93 | $4.94 |
Technical Indicators
Market Signals| Indicator | HFFG | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 19.14 | 37.23 |
| Support Level | $1.47 | $2.13 |
| Resistance Level | $1.75 | $2.37 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 1.34 | 16.32 |
Price Performance
Historical ComparisonAbout HFFG HF Foods Group Inc.
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The company's business consists of one operating segment; HF Group, which operates solely in the United States. The company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.